

Table S1. Disease manifestations in 293 patients included in the study cohort. Cumulative disease manifestations since the diagnosis and disease manifestations during the follow-up according to the duration, but irrespective to the level of remission achieved are reported.

No. patients	Total study cohort 293	Unremitted disease 35	1-year remission 27	2-year remission 47	3-year remission 45	4-year remission 26	≥5-year remission 113	p
Lagtime onset-diagnosis*, months, mean ±SD	16.6±21.04	18.5±22.2	13.2±10.8	16.4±24.5	18.6±29.3	10.7±5.2	15.7±15.2	n.s.
ANA positivity, No. (%)	293 (100)	35 (100)	27 (100)	47 (100)	45 (100)	26 (100)	113 (100)	n.s.
Anti-dsDNA Ab, No. (%)	246 (83.9)	32 (91.4)	26 (96.3)	40 (85.1)	39 (86.7)	24 (92.3)	85 (75.2)	0.028
Anti-U1RNP Ab, No. (%)	77 (26.2)	16 (45.7)	9 (33.3)	12 (25.5)	10 (22.2)	5 (19.2)	25 (22.5)	0.05
Low C3 or C4 serum levels, No. (%)	257 (87.7)	29 (82.9)	26 (96.3)	41 (87.2)	41 (91.1)	22 (84.6)	98 (86.5)	n.s.
Antiphospholipid Abs, No. (%)	96 (32.8)	11 (31.4)	11 (40.7)	13 (27.7)	19 (42.2)	7 (26.9)	35 (31.0)	n.s.
Disease manifestations overall								
Constitutional symptoms [§] , No. (%)	241 (82.2)	28 (80.0)	23 (85.2)	41 (87.2)	38 (86.4)	23 (88.5)	88 (79.3)	n.s.
Skin rashes, No. (%)	182 (62.1)	29 (82.9)	15 (63.6)	32 (68.1)	29 (64.4)	12 (46.2)	65 (57.1)	0.001
Arthritis/Inflammatory arthralgias, No. (%)	218 (74.4)	27 (77.1)	22 (81.5)	35 (74.5)	36 (80)	19 (73.1)	79 (70.5)	n.s.
Serositis, No. (%)	76 (25.9)	14 (40)	11 (40.7)	15 (31.9)	11 (24.49)	5 (19.2)	20 (17.9)	0.035
Glomerulonephritis, No. (%)	168 (57.3)	25 (71.4)	21 (77.8)	28 (59.6)	28 (62.2)	14 (53.8)	52 (46.4)	0.019
NP manifestations, No. (%)	39 (13.3)	5 (14.3)	4 (14.8)	9 (19.1)	8 (17.8)	3 (11.5)	10 (8.9)	n.s.
Vasculitis, No. (%)	34 (11.6)	9 (25.7)	4 (14.8)	7 (14.9)	6 (13.3)	3 (11.5)	5 (4.5)	0.021
Haematological involvement, No. (%)	111 (37.8)	14 (40.0)	17 (63.0)	20 (42.6)	18 (40.0)	12 (46.2)	30 (26.5)	0.028
Antiphospholipid syndrome, No. (%)	40 (13.7)	6 (17.1)	5 (18.5)	4 (8.5)	6 (13.3)	4 (15.4)	15 (13.3)	n.s.
Manifestations during follow-up								
Skin rashes, No. (%)	74 (25.2)	25 (71.4)	12 (44.4)	14 (29.8)	9 (20.0)	6 (23.1)	8 (7.1)	<0.001
Arthritis, No. (%)	82 (28.0)	12 (34.3)	16 (59.3)	21 (44.7)	18 (40.0)	7 (26.9)	8 (7.1)	<0.001
Serositis, No. (%)	17 (5.8)	3 (8.6)	2 (7.4)	5 (10.6)	5 (11.1)	1 (3.8)	1 (0.9)	n.s.
Glomerulonephritis, No. (%)	103 (35.2)	20 (57.1)	18 (66.7)	23 (48.9)	20 (44.4)	9 (34.6)	13 (11.5)	<0.001
NP manifestations, No. (%)	22 (7.5)	4 (11.4)	2 (7.4)	8 (17.0)	6 (13.3)	1 (3.8)	1 (0.9)	0.005
Vasculitis, No. (%)	17 (5.8)	6 (17.1)	2 (7.4)	6 (12.8)	2 (4.4)	0 (0)	1 (0.9)	0.002

Haematological involvement, No.(%)	49 (16.7)	8 (22.9)	9 (33.3)	13 (27.7)	9 (20.0)	8 (30.8)	2 (1.8)	<0.001
Number of flares /patient/year, mean±SD	0.25±0.29	0.57±0.39	0.52±0.28	0.42±0.23	0.23±0.19	0.18±0.14	0.03±0.08	<0.001

ANA, anti-nuclear antibodies; Anti-dsDNA Ab, anti double-stranded DNA antibodies; C3/C4, complement fractions; NP, neuropsychiatric; SD, standard deviation.

*Lagtime onset-diagnosis: defined as the time between the onset of the first American Rheumatism Association (ARA) criterion and the medical diagnosis

§constitutional symptoms: fever, anorexia, lymphadenopathy or unintentional weight loss due to SLE

p values refer to ANOVA test for continuous variables and chi square test (5 degrees of freedom) for dichotomous variables freedom (comparison among unremitted, one-, two-, three-, four- and five or more year remitted patients).